IVD Assay Development Market (2026-2036)

The growth of this market is mainly driven by labelling requirements that specify the studies an in vitro diagnostic developer must complete before a product insert can be written, by a design and development framework that moved to Clause 7.3 of ISO 13485 when the amended quality system regulation took effect in the first month of the forecast period, by European certification milestones that oblige manufacturers to assemble performance evaluation and technical documentation inside the first years of the period, by molecular assay development that requires capability most diagnostic developers do not hold internally, and by small and emerging diagnostic companies reaching the development stage without laboratories or regulatory functions of their own. The deliverable set in this market is specified by regulation rather than negotiated with the customer, which makes demand predictable and the scope of each engagement difficult to reduce.

However, factors such as the reluctance of diagnostic companies to place a proprietary assay concept with a provider that serves competitors, development timelines that place revenue recognition a year or more after an award, the dependence of a development programme on the customer own funding which makes the work vulnerable to a financing round that does not close, and the concentration of purchasing among a small number of large diagnostic companies able to develop internally are expected to restrain the growth of this market to some extent. A provider also carries the regulatory expectations of its customers without owning the product, so compliance investment raises its cost base without raising the fee it can charge.

The labelling requirements at 21 CFR 809.10(b), under which the labelling accompanying an in vitro diagnostic product must state, in one place and in the specified format and order, the proprietary and established names, the intended use including the type of procedure, a summary and explanation of the test with a balanced statement of its merits and limitations, the principles of the procedure, reagent and instrument information, specimen collection and preparation including known interfering substances and storage conditions, a step-by-step procedure, the calculation of results, the limitations of the procedure, expected values, specific performance characteristics, a bibliography, the manufacturer details and the date of the last labelling revision sets out the deliverable set of an assay development programme in regulation rather than leaving it to be agreed between developer and provider. Under the same requirements performance characteristics must cover accuracy, precision, specificity and sensitivity as appropriate, related to a generally accepted method using biological specimens from normal and abnormal populations, together with a statement summarising the data on which they are based, expected values must give the ranges with an explanation of how they were established and the populations studied, the procedure must specify calibration including reference materials, blanks and the standard curve together with the range of measurable values, quality control must state whether positive and negative controls are required and define satisfactory performance limits, and reagent information must state storage conditions and the signs of instability. Almost every item on that list is the output of a study rather than a writing exercise, so a developer cannot produce the insert without having run the work, and a provider selling assay development is selling the studies that populate it. The scope of an engagement is therefore difficult for a customer to reduce without leaving a gap a reviewer will find.

Specific performance characteristics covering accuracy, precision, specificity and sensitivity against a generally accepted method using normal and abnormal populations are the core assay development deliverable, the requirement to state storage conditions and the signs of instability is what creates the stability testing offering, the reagent and instrument information requirements reach into packaging and presentation, and the expected values requirement calls for population studies that a small developer rarely has the samples to perform. Regulatory support sits around all of them because the insert and the technical documentation it supports have to be assembled into a submission.

The amended 21 CFR part 820, now titled the Quality Management System Regulation, which at 820.7 incorporates by reference Clause 3 of ISO 9000:2015 and ISO 13485:2016, reserves subparts C through O including the former design controls section at 820.30, and applies design and development requirements through 820.10(c) by reference to Clause 7.3 of ISO 13485 changed the framework a development programme has to be documented against in the first month of the forecast period. Design and development planning, inputs, outputs, review, verification, validation and transfer records now have to be structured to Clause 7.3 of ISO 13485 rather than to the former design controls section, and a provider whose templates and procedures were built around the superseded structure has to rework them while its customers ask for the restructuring to be done on their files as well. Providers already operating ISO 13485 quality systems for their European business carried most of what the amended regulation requires and have gained work from those that did not.

The transitional deadlines under Articles 110(3) and 110(4) of the In Vitro Diagnostic Regulation as amended by Regulation (EU) 2024/1860, which run to 31 December 2027 for class D devices, 31 December 2028 for class C devices and 31 December 2029 for class B and sterile class A devices, subject to the manufacturer having had a quality management system in place under Article 10(8) by 26 May 2025, having applied to a notified body by the date set for its class and having signed a written agreement with that notified body four months later pulls performance evaluation and technical documentation work forward in Europe. A manufacturer taking a legacy assay through conformity assessment has to assemble analytical and clinical performance evidence to the standard the regulation sets rather than to the standard that supported the original directive registration, and with class C applications due by 26 May 2026 and signed notified body agreements by 26 September 2026 that work falls in the opening years of the period. Regulatory support is consequently the second fastest-growing offering in this market, and it is bought by established manufacturers rather than by the emerging developers that buy assay development.

Customers in this market divide into two groups that buy different things. Emerging diagnostic companies with a biomarker, an algorithm or a technology but no laboratory buy the whole development programme, from format selection and antibody or primer pairing through analytical validation to design transfer, and pay for it out of investment funding. Established diagnostic manufacturers buy individual pieces, most often stability testing, packaging development or regulatory documentation for a product they developed themselves, and pay for it out of operating budget. The first group generates larger engagements and higher risk, the second smaller engagements and reliable repeat work.

Assay development converts into manufacturing supply more often than it does into a single report. A provider that has developed an assay holds the process knowledge, the validated method and the documentation that any alternative manufacturer would have to recreate at the customer cost, so the development contract frequently decides who manufactures the product for its commercial life. That is why providers combining development with manufacturing capacity price development work against the supply that follows rather than against its own cost, and why development-only specialists are at a structural disadvantage in competing for it.

Molecular assay development requires capability that an immunoassay or clinical chemistry developer does not already hold, covering oligonucleotide design, primer and probe optimisation, enzyme and master mix formulation, extraction chemistry and frequently lyophilization, and the validation burden is heavier because inhibition, extraction efficiency and multiplex interaction all have to be characterised. A diagnostic company extending into molecular testing therefore faces a capability decision rather than a capacity one, which is why molecular diagnostics is the fastest-growing technology in this market and why the providers positioned in it command higher fees than those serving established immunoassay formats.